161886-96-0

Basic information

• Product Name: 3-THIEN-3-YLANILINE
• Synonyms: 3-(3-THIENYL)ANILINE;AKOS BAR-0367;3-THIEN-3-YLANILINE;3-THIOPHEN-3-YL-PHENYLAMINE;3-Thien-3-ylaniline 97%;3-(3-Aminophenyl)thiophene;3-(Thiophen-3-yl)aniline;3-(Thien-3-yl)aniline97%
• CAS NO: 161886-96-0
• Molecular Formula: C₁₀H₉NS
• Molecular Weight: 175.25
• Mol File: 161886-96-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 89 °C
• Boiling Point: 312.5 °C at 760 mmHg
• Flash Point: 142.8 °C
• Appearance: /
• Density: 1.196 g/cm³
• Vapor Pressure: 0.000525mmHg at 25°C
• Refractive Index: 1.65
• PKA: 4.30±0.10(Predicted)
• CAS DataBase Reference: 3-THIEN-3-YLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-THIEN-3-YLANILINE(161886-96-0)
• EPA Substance Registry System: 3-THIEN-3-YLANILINE(161886-96-0)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 161886-96-0(Hazardous Substances Data)

Usage

General Description

3-Thien-3-ylaniline is a chemical compound with the molecular formula C10H9NS. It is an aniline derivative with a thienyl group attached to the amine nitrogen atom. 3-THIEN-3-YLANILINE has the potential to be used in various applications, such as in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block for the preparation of organic materials and in the field of organic electronics. Additionally, 3-thien-3-ylaniline has been studied for its potential biological activities, including its antimicrobial and anti-inflammatory properties. Overall, the compound shows promise for various industrial and biological applications due to its unique combination of chemical and biological properties.

InChI:InChI=1/C10H9NS/c11-10-3-1-2-8(6-10)9-4-5-12-7-9/h1-7H,11H2

Upstream product

• 6165-69-1 Thien-3-ylboronic acid 
• 591-19-5 m-Bromoaniline 
• 872-31-1 3-Bromothiophene 
• 30418-59-8 3-Aminophenylboronic acid 

Downstream Products

• 1415022-42-2 C₁₂H₉Cl₂NOS 
• 1071925-72-8 N-(3-(thiophen-3-yl)phenyl)-4-(pyridin-3-yl)benzamide 

Relevant articles and documents

Diarylureas Containing 5-Membered Heterocycles as CB1 Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation

Allosteric modulators have attracted significant interest as an alternate strategy to modulate CB1 receptor signaling for therapeutic benefits that may avoid the adverse effects associated with orthosteric ligands. Here we extended our previous structure-activity relationship studies on the diarylurea-based CB1 negative allosteric modulators (NAMs) by introducing five-membered heterocycles to replace the 5-pyrrolidinylpyridinyl group in PSNCBAM-1 (1), one of the first generation CB1 allosteric modulators. Many of these compounds had comparable potency to 1 in blocking the CB1 agonist CP55,940 stimulated calcium mobilization and [35S]GTP-γ-S binding. Similar to 1, most compounds showed positive cooperativity by increasing [3H]CP55,940 binding, consistent with the positive allosteric modulator (PAM)-antagonist mechanism. Interestingly, these compounds exhibited differences in ability to increase specific binding of [3H]CP55,940 and decrease binding of the antagonist [3H]SR141716. In saturation binding studies, only increases in [3H]CP55,940 Bmax, but not Kd, were observed, suggesting that these compounds stabilize low affinity receptors into a high affinity state. Among the series, the 2-pyrrolyl analogue (13) exhibited greater potency than 1 in the [35S]GTP-γ-S binding assay and significantly enhanced the maximum binding level in the [3H]CP5,5940 binding assay, indicating greater CB1 receptor affinity and/or cooperativity.

Design, synthesis and biological evaluation of N-arylphenyl-2,2- dichloroacetamide analogues as anti-cancer agents

Our earlier research has shown that N-phenyl-2,2-dichloroacetamide analogues had much higher anti-cancer activity than the lead compound sodium dichloroacetate (DCA). In this current study, a variety of N-arylphenyl-2,2- dichloroacetamide analogues were synthesized via Suzuki coupling reaction and their anti-cancer activity was evaluated. The results showed that N-terphenyl-2,2-dichloroacetamide analogues had satisfactory anti-cancer activity. Among them, N-(3,5-bis(benzo[d][1,3]dioxol-5-yl)phenyl)-2,2- dichloroacetamide (6 k) had an IC50 of 2.40 μM against KB-3-1 cells, 1.04 μM against H460 cells and 1.73 μM against A549 cells.

Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to amino or pyridylamino cyclobutane derivatives.